On the other hand, PRL compensates for erythropoietin (EPO) deficiency in patients on dialysis because of chronic kidney failure, and both in vitro and in vivo studies suggest that PRL can accelerate lymphoid and myeloid reconstitution and promote haematopoiesis 16, 17, 18. This evidence concerns the gene EPO and chronic renal failure syndrome.